TORNTPHARM

Torrent Pharmaceuticals Share Price

₹3,167.10 +65.15 (2.1%)

23 Nov, 2024 09:54

SIP TrendupStart SIP in TORNTPHARM

Start SIP

Performance

  • Low
  • ₹3,102
  • High
  • ₹3,190
  • 52 Week Low
  • ₹2,026
  • 52 Week High
  • ₹3,591
  • Open Price₹3,102
  • Previous Close₹3,102
  • Volume290,862

Investment Returns

  • Over 1 Month -5.17%
  • Over 3 Month -5.81%
  • Over 6 Month + 18.9%
  • Over 1 Year + 49.99%
SIP Lightning

Smart Investing Starts Here Start SIP with Torrent Pharmaceuticals for Steady Growth!

Invest Now

Torrent Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 59.5
  • PEG Ratio
  • 1.7
  • Market Cap Cr
  • 107,189
  • P/B Ratio
  • 15.6
  • Average True Range
  • 81.82
  • EPS
  • 51.42
  • Dividend Yield
  • 0.9
  • MACD Signal
  • -67.46
  • RSI
  • 44.06
  • MFI
  • 21.48

Torrent Pharmaceuticals Financials

Torrent Pharmaceuticals Technicals

EMA & SMA

Current Price
₹3,167.10
+ 65.15 (2.1%)
pointer
  • stock-down_img
  • Bullish Moving Average 8
  • stock-up_img
  • Bearish Moving Average 8
  • 20 Day
  • ₹3,193.24
  • 50 Day
  • ₹3,263.37
  • 100 Day
  • ₹3,201.26
  • 200 Day
  • ₹2,972.60

Resistance and Support

3152.95 Pivot Speed
  • R3 3,291.50
  • R2 3,240.60
  • R1 3,203.85
  • S1 3,116.20
  • S2 3,065.30
  • S3 3,028.55

What's your outlook on Torrent Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Torrent Pharmaceuticals Ltd. is a leading Indian pharmaceutical company, offering a wide range of branded and generic medicines. It focuses on therapeutic areas like cardiovascular, central nervous system, gastroenterology, and diabetes, serving both domestic and international markets.

Torrent Pharmaceuticals has an operating revenue of Rs. 11,225.00 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 22% is great, ROE of 24% is exceptional. The company has a reasonable debt to equity of 23%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It has recently broken out of a base in its weekly chart but failed to keep its momentum and is trading around -13% from the pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 71 which is a FAIR score but needs to improve its earnings, a RS Rating of 62 which is FAIR indicating the recent price performance, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 35 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock definitely has some strength, you may want to examine it in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Torrent Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-25 Quarterly Results
2024-07-23 Quarterly Results
2024-05-24 Audited Results & Final Dividend
2024-02-02 Quarterly Results & Interim Dividend
2023-10-23 Quarterly Results
Date Purpose Remarks
2024-06-21 FINAL Rs.6.00 per share(120%)Final Dividend
2024-02-12 INTERIM Rs.22.00 per share(440%)Interim Dividend
2023-06-23 FINAL Rs.8.00 per share(160%)Final Dividend
2023-02-03 INTERIM Rs.14.00 per share(280%)Interim Dividend
2022-06-06 FINAL Rs.8.00 per share(160%)Final Dividend
Date Purpose Remarks
2022-07-11 Bonus Rs.0.00 issue of equity shares in the ratio of 1:1 of Rs. 5/-.

Torrent Pharmaceuticals F&O

Torrent Pharmaceuticals Shareholding Pattern

71.25%
3.69%
1.89%
14.46%
0%
4.34%
4.37%

About Torrent Pharmaceuticals

Torrent Pharmaceuticals Limited (TPL) is one of India’s leading pharmaceutical companies, with a strong presence in research and development, manufacturing and marketing. In terms of oncology specialty therapies, TPL is one of India's leading pharma companies. The specialties business includes three major therapeutic areas: Cancer Chemotherapy, Cardiology, and Anti-Infectives. TPL has established itself as a leader in its field by providing affordable medicines to patients across India. In addition to cancer care, TPL is also recognized for its anti-infective products, such as Ciprofloxacin which are widely used in treating bacterial infections. 

Business Verticals

Torrent Pharmaceuticals is a global specialty pharmaceutical and OTC medicines player. The Company has two divisions: Pharmaceuticals and Consumer Healthcare (OTC). 

Torrent's Pharmaceuticals division consists of three major therapeutic areas: Cardiovascular, Central Nervous System (CNS) and Metabolic Diseases. Its products include branded formulations for treating cardiovascular diseases, central nervous system disorders and metabolic diseases. They are available as tablets, capsules, injectables and syrups. 

It also offers active pharmaceutical ingredients (APIs), which other companies use to manufacture their drugs. In addition, Torrent's Pharmaceuticals markets its consumer healthcare products through its direct sales force in India. Torrent has manufacturing facilities across India and exports its products to over 80 countries worldwide.

Milestones

1959 - Shri U. N. Mehta ventured in the pharmaceutical  industry.

1971 - Trinity Laboratories was renamed as Torrent Pharmaceuticals Limited.

1980 - The first manufacturing facility was established in Ahmedabad at Vatva.

1983 - Torrent Pharmaceuticals enters international markets with the first export order to the USSR.

1984
Torrent Laboratories Limited wins Chemexcil Export Award.
Torrent Laboratories Limited received the Udyog Ratna Award.

1985
After demonstrating exceptional export performance, Torrent Laboratories Limited is honoured with the IMC Golden Jubilee Endowment Award.
Torrent Exports Limited wins the Gujarat Government export award.
IDMA awarded Torrent Laboratories Limited the Quality Excellence Award.

1986
Torrent Laboratories Limited wins the Chemexcil Export Award third time in a row.
The IDMA Quality Excellence Award was presented to Torrent Laboratories Limited.
Torrent Exports Limited wins the Gujarat Government export award again.

1987
Torrent Laboratories Limited wins the Chemexcil Export Award for the fourth consecutive year.
The Gujarat government awarded Torrent Exports Limited an export award for the third time.

1988 - Torrent Laboratories Limited wins the Chemexcil Export Award for the fifth consecutive year.

1989
Torrent Laboratories establish their second manufacturing plant.
Chemexcil Trishul Award for Highest Pharma Exports awarded to Torrent Exports Limited.
Torrent Pharmaceuticals Limited wins the IDMA Quality Excellence Award.

1990
Torrent Exports Limited wins the National Export Award.
Torrent Pharmaceuticals Ltd wins the International Friendship's Pride of Asia International award for excellence in pharmaceutical products.

1992 - Torrent Pharmaceuticals Limited wins the IDMA Quality Excellence Award for the second time.

1995 - The Torrent Gujarat Biotech Limited plant gets commissioned.

1999
Torrent Pharmaceuticals Ltd gets revamped. Three new divisions, Prima, Vista, and Psycan, are formed.
Torrent Research Center receives its first patent for a new chemical entity.
Torrent Exports Limited wins the GCCI Export Recognition Award
Torrent Pharma wins the IDMA Gold Trophy.

2000
Torrent Research Center is awarded the OECD Standards of Good Laboratory Practices Certificate by the Dutch Health Ministry.
The Indrad Plant gets the ISO 9001:2000 certification.

2001
In terms of Return on Capital Employed, Torrent Pharma was ranked among the top ten Indian companies (ET - BCG Study Feb - 2001).
Torrent Pharmaceuticals wins the 'Best Suppliers' award by the Sri Lankan State Pharmaceutical Corporation.
Torrent Pharma wins the IDMA Quality Excellence Award Gold Trophy for its Formulation facility. It is awarded the Silver Trophy for its API manufacturing facility as well.
Torrent do Brasil Ltda. was founded and incorporated in Brazil.

2002
The AGE (Advanced Glycosylation End-products) molecule is discovered and patented.
Torrent Pharma's Indrad Plant gets ISO 14001:1996 and OHSAS 18001:1999 certifications.
Torrent's R&D Center with ISO/IEC 17025:1999 gets accredited by the National Accreditation Board for Testing and Calibration Laboratories for its facilities (NABL).
Torrent Pharmaceuticals Ltd launches a new marketing division, MIND.
Torrent Research Center develops its own Dual Retard Inlay Technology, Compact Tablet Technology, Gastro Retentive System, and Multiparticulate / Matrix Based SR / Modified Release Formulations.

2003
Torrent Pharma Inc. is founded and incorporated in the United States.
Torrent Pharmaceuticals Manufacturing Plant receives GMP certification from the European Union.
Torrent Pharma Philippines Inc. is founded and incorporated.
Torrent Pharma received the Gold Trophy for the IDMA Quality Excellence Award again for its formulation and API manufacturing facilities.

2006
The API and formulation manufacturing facilities in Indrad (Gujarat, India) receive the most coveted US FDA approval.
South African Torrent Pharma and Pharma Dynamics (Pty) Ltd signed a Technical Agreement to supply various products.

2007
Indrad Plant with ISO 9001: 2000 (Quality Management System), ISO 14001:2004 (Environmental Management System), and OHSAS 180001:1999 (Occupational Health and Safety Management System) get certified by ISOQAR, a UKAS accredited body.
Sikkim Plant construction begins.

2008 - The Baddi Plant gets the prestigious GMP certification from the Government of Upper Bavaria in Germany.

2009
Novo Nordisk commissions a dedicated formulation and packaging unit to Torrent Pharmaceuticals Ltd for exclusively manufacturing Insulin.
AstraZeneca signed a license and supply agreement to market its products in the international market.
Baddi Plant gets a five-star rating from the British Safety Council.

2010
Baddi Plant receives the OHSAS Audit 18001:2007 certification. Uganda's regulatory authority approves the Baddi Plant facility.
An advanced facility for Stability Studies gets established at the Indrad Plant.
Torrent Pharmaceuticals Ltd enter the field of gynaecology therapy.
Laboratories Torrent S.A. de C.V Mexico begins its commercial operations.
Dahej manufacturing facility construction begins.

2011
The Sikkim Plant begins operations.
Torrent Research Center creates an indigenous nasal drug delivery system.
Torrent Pharmaceuticals Ltd launches Sparsh, a dedicated division to serve the Dermatology Segment.

2012
The Indrad Plant is bestowed with the Sword of Honor for Occupational Health and Safety by the British Safety Council.
Torrent Research Center discovers the Topical Foams system.

2013 - Torrent Pharma signs a licensing agreement with Reliance Life Sciences for three biosimilars: rituximab, adalimumab, and cetuximab.

2014
Elder Pharma's identified Indian Branded Formulation Business in India and Nepal gets acquired by Torrent Pharmaceuticals. 
Nephro, a dedicated division is established to exclusively serve the Nephrology Segment.
The Dahej Plant of Torrent Pharma initiates their operations.

2015
10th CNBC TV18 India Business Leader Awards 2014 witnesses the victory of Torrent Pharma as the Most Promising Company of the Year.
Torrent acquired Zyg Pharma.

2016
The Dahej Plant gets the USFDA certification.
Torrent Pharmaceuticals acquires API manufacturing unit of Hyderabad-based Glochem Industries Limited.

2017
Torrent Pharmaceuticals acquire Unichem's domestic and Nepal operations along with its Sikkim manufacturing facility.
Business World Magazine names them as one of the top five 'Fastest Growing Companies (Middleweights Category)'.
Executive Chairman, is named as one of India's Most Valuable CEOs in the by Business World Magazine.
Torrent Pharmaceuticals acquires all Novartis' Women Healthcare brands.

2018 - Torrent makes its first overseas purchase by acquiring Bio-Pharm Inc. (BPI), based in the United States along with a US FDA-registered manufacturing facility. 

2019 - Torrent and Glenmark sign a licensing agreement for co-marketing Remogliflozin Etabonate pan-India.

2021
In India, Torrent Pharma launches MSD (a trademark of Merck & Co., Inc, Kenilworth, NJ, USA) and Ridgeback's Molnupiravir under the brand name Molnutor®.
Torrent Pharma Signs Voluntary Licensing Agreement with Lilly to produce and distribute Baricitinib for Covid-19 in India.

2022 
Torrent finalizes the acquisition of Dr. Reddy's Laboratories Ltd. four brands: "Styptovit-E," "Finast," "Finast-T," and "Dynapress."
Torrent Pharma signs a licensing agreement with Medicine Patent Pool for the production and marketing of a generic version of Pfizer's Oral COVID-19 Treatment.

View More
  • NSE Symbol
  • TORNTPHARM
  • BSE Symbol
  • 500420
  • ISIN
  • INE685A01028

Similar Stocks to Torrent Pharmaceuticals

Torrent Pharmaceuticals FAQs

Torrent Pharmaceuticals share price is ₹3,167 As on 23 November, 2024 | 09:40

The Market Cap of Torrent Pharmaceuticals is ₹107189 Cr As on 23 November, 2024 | 09:40

The P/E ratio of Torrent Pharmaceuticals is 59.5 As on 23 November, 2024 | 09:40

The PB ratio of Torrent Pharmaceuticals is 15.6 As on 23 November, 2024 | 09:40

Torrent Pharmaceuticals Ltd recorded a net sales of INR 8508 crores in the year ending March 2022.

Torrent Pharmaceuticals Ltd stock is a good option for long-term investment since the stock prices indicate a strong buying trend.

The company's shares can be bought online by opening a demat account with 5paisa and verifying the KYC documents. You can also use our mobile app for a fast experience.

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23